Reactive arthritis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence of reactive arthritis following a gastrointestinal or genitourinary infection is approximately 1-3.1 cases per 100,000 individuals worldwide.<ref name="pmid18272671">{{cite journal |vauthors=Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J |title=Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study |journal=Ann. Rheum. Dis. |volume=67 |issue=12 |pages=1689–96 |date=December 2008 |pmid=18272671 |doi=10.1136/ard.2007.083451 |url=}}</ref>
*The incidence of reactive arthritis following a gastrointestinal or genitourinary infection is approximately 3-27 cases per 100,000 individuals worldwide.<ref name="pmid18272671">{{cite journal |vauthors=Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J |title=Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study |journal=Ann. Rheum. Dis. |volume=67 |issue=12 |pages=1689–96 |date=December 2008 |pmid=18272671 |doi=10.1136/ard.2007.083451 |url=}}</ref>
*The incidence rate of reactive arthritis varies with the underlying infection.<ref name="pmid24288942">{{cite journal |vauthors=Ajene AN, Fischer Walker CL, Black RE |title=Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis |journal=J Health Popul Nutr |volume=31 |issue=3 |pages=299–307 |date=September 2013 |pmid=24288942 |pmc=3805878 |doi= |url=}}</ref>
*The incidence rate of reactive arthritis varies with the underlying infection.<ref name="pmid24288942">{{cite journal |vauthors=Ajene AN, Fischer Walker CL, Black RE |title=Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis |journal=J Health Popul Nutr |volume=31 |issue=3 |pages=299–307 |date=September 2013 |pmid=24288942 |pmc=3805878 |doi= |url=}}</ref>
**The incidence rate of reactive arthritis following Campylobacter infection is 900 per 100,000 cases.
**The incidence rate of reactive arthritis following Campylobacter infection is 900 per 100,000 cases.
**The incidence rate of reactive arthritis following Salmonella and Shigella infection is 1200 per 100,000 cases.
**The incidence rate of reactive arthritis following Salmonella and Shigella infection is 1200 per 100,000 cases.
Globally, the annual incidence has been reported between 0.6 to 27 per 100,000, and the prevalence is estimated to be 30 to 40 per 100,000 adults [3,4,6,14].


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The prevalence of reactive arthritis is approximately 0 to 40 per 100,000 individuals worldwide.<ref name="pmid20025528">{{cite journal |vauthors=Townes JM |title=Reactive arthritis after enteric infections in the United States: the problem of definition |journal=Clin. Infect. Dis. |volume=50 |issue=2 |pages=247–54 |date=January 2010 |pmid=20025528 |doi=10.1086/649540 |url=}}</ref><ref name="pmid19373091">{{cite journal |vauthors=Rohekar S, Pope J |title=Epidemiologic approaches to infection and immunity: the case of reactive arthritis |journal=Curr Opin Rheumatol |volume=21 |issue=4 |pages=386–90 |date=July 2009 |pmid=19373091 |doi=10.1097/BOR.0b013e32832aac66 |url=}}</ref><ref name="pmid22100285">{{cite journal |vauthors=Hannu T |title=Reactive arthritis |journal=Best Pract Res Clin Rheumatol |volume=25 |issue=3 |pages=347–57 |date=June 2011 |pmid=22100285 |doi=10.1016/j.berh.2011.01.018 |url=}}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Revision as of 14:16, 5 April 2018

Reactive arthritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Reactive arthritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Reactive arthritis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Reactive arthritis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Reactive arthritis epidemiology and demographics

CDC on Reactive arthritis epidemiology and demographics

Reactive arthritis epidemiology and demographics in the news

Blogs onReactive arthritis epidemiology and demographics

Directions to Hospitals Treating Reactive arthritis

Risk calculators and risk factors forReactive arthritis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of reactive arthritis following a gastrointestinal or genitourinary infection is approximately 3-27 cases per 100,000 individuals worldwide.[1]
  • The incidence rate of reactive arthritis varies with the underlying infection.[2]
    • The incidence rate of reactive arthritis following Campylobacter infection is 900 per 100,000 cases.
    • The incidence rate of reactive arthritis following Salmonella and Shigella infection is 1200 per 100,000 cases.

Globally, the annual incidence has been reported between 0.6 to 27 per 100,000, and the prevalence is estimated to be 30 to 40 per 100,000 adults [3,4,6,14].

Prevalence

  • The prevalence of reactive arthritis is approximately 0 to 40 per 100,000 individuals worldwide.[3][4][5]
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop reactive arthritis.
  • Reactive arthritis commonly affects young adults
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • Reactive arthritis affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J (December 2008). "Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study". Ann. Rheum. Dis. 67 (12): 1689–96. doi:10.1136/ard.2007.083451. PMID 18272671.
  2. Ajene AN, Fischer Walker CL, Black RE (September 2013). "Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis". J Health Popul Nutr. 31 (3): 299–307. PMC 3805878. PMID 24288942.
  3. Townes JM (January 2010). "Reactive arthritis after enteric infections in the United States: the problem of definition". Clin. Infect. Dis. 50 (2): 247–54. doi:10.1086/649540. PMID 20025528.
  4. Rohekar S, Pope J (July 2009). "Epidemiologic approaches to infection and immunity: the case of reactive arthritis". Curr Opin Rheumatol. 21 (4): 386–90. doi:10.1097/BOR.0b013e32832aac66. PMID 19373091.
  5. Hannu T (June 2011). "Reactive arthritis". Best Pract Res Clin Rheumatol. 25 (3): 347–57. doi:10.1016/j.berh.2011.01.018. PMID 22100285.

Template:WS Template:WH